ClinicalTrials.gg
CompletedNCT02549092Updated Nov 28, 2023Results posted

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

A Phase 3 interventional study of Optimized Medical Treatment and Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease, sponsored by AbbVie. Completed at 38 sites in 9 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.

Enrollment
18th of 50
89 · median 56
Started
2015
with 3 others
Phase 3
12 of 51
none open now
Registered
38th of 51
by date
Lead sponsor
3 of 51
AbbVie

Among the 51 studies testing levodopa in Parkinson Disease, this one is the 18th largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2015, is one of 12 in phase 3, and was the 38th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About levodopa

Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing levodopa in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.

Read the detailed description

The study will consist of 3 sequential parts:

Part 1: Screening period. The screening period will consist of 3 visits, Visit 1 (V1), Visit 2 ([V2] [optional]) and the Randomization Visit (V3) in which the participant will be assessed to determine eligibility. The duration of the Screening Period can be between 30 to 67 days to accommodate the required procedures, training and collection of diaries, and to allow for stabilization of anti-PD medications and medications to treat NMS. All anti-PD medications and medications to treat NMS are required to be stable for a minimum of 30 days prior to randomization.

Part 2: Treatment period. Those participants randomized to OMT at the end of V3 will remain on their current optimized regimen. The day after randomization will be considered Day 1 of their treatment period and participants will have study visits at the end of Weeks 2, 6, 12, and 26. All participants randomized to the LCIG group should have all anti-PD medications, with the exception of levodopa formulations, tapered off within 14 days after randomization. Optional nasojujunal (NJ) and/or percutaneous endoscopic gastrostomy with a jejunal tube (PEG-J) placement will then occur. After that, the participant may begin initiation and titration of LCIG infusion to be adjusted to obtain the optimal clinical response. The day of initial NJ or PEG-J placement will be considered Day 1 for participants in the LCIG group. Study visits happen at the end of Weeks 2, 6, 12, and 26.

Part 3: Extension/Transition Period. Eligible participants who complete the 26 week study may continue into the Extension Period of the study. Participants in the LCIG arm will have study drug dispensation every 4 weeks and will have study visits every 6 months. Participants from the OMT arm will undergo the NJ (optional) and PEG-J procedures, titration, plus have visits at 2 weeks, 6 weeks, 3 months and 6 months post NJ or PEG-J. Participants will then continue to receive study drug every 4 weeks and will have study visits every 6 months until Duodopa is commercially available. Transition to a Post-Trial Access protocol will be possible if Duodopa does not become commercially available in a location.

03

Conditions studied

  • Advanced Parkinson's Disease

Browse trials for

Keywords

  • levodopa-carbidopa intestinal gel
  • levodopa
  • carbidopa
  • Advanced Parkinson's Disease
  • Non-Motor Symptom Scale NMSS
  • Parkinson's Disease Sleep Scale PDSS-2
  • efficacy
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant(s) must have a diagnosis of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.
  2. Participant(s) demonstrates persistent motor fluctuations in spite of individually optimized treatment.
  3. The participant's Parkinson's disease is levodopa-responsive.
  4. Participant(s) has had optimized treatment with available anti-PD medication and their motor symptoms are judged inadequately controlled on this optimized treatment. Optimized treatment is defined as the maximum therapeutic effect obtained with pharmacological antiparkinsonian therapies when no further improvement is expected regardless of any additional manipulations of levodopa and/or other antiparkinsonian medication. This will be based on the Investigator's clinical judgment.
  5. Male or female participant(s) must be at least 30 years of age.
  6. Minimum Parkinson's Disease Sleep Scale 2 (PDSS-2) total score of 18 at Baseline assessment.

Exclusion criteria

Exclusion Criteria:

  1. Participant's PD diagnosis is unclear or there is a suspicion that the subject has a parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body disease) or other neurodegenerative disease that might mimic the symptoms of PD.
  2. Participant(s) has undergone neurosurgery for the treatment of Parkinson's disease.
  3. Known to levodopa, carbidopa or radiopaque material.
  4. Participant(s) has to levodopa (e.g. narrow angle glaucoma, malignant melanoma).
  5. Participant(s) experiencing sleep attacks or clinically significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any point during the three months prior to the Screening evaluation as judged by the Principal Investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Active comparator
    Optimized Medical Treatment (OMT)

    Participants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG.

    Drug: Optimized Medical Treatment · Drug: Levodopa-Carbidopa Intestinal Gel · Device: Nasojejunal (NJ) tube · Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube

  • Experimental
    Levodopa-Carbidopa Intestinal Gel (LCIG)

    Participants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated. The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day. Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG.

    Drug: Levodopa-Carbidopa Intestinal Gel · Device: Nasojejunal (NJ) tube · Device: Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube

Interventions

  • DrugOptimized Medical Treatment

    Oral, sublingual or transdermal anti-PD medications and medications to treat NMS per Investigator discretion and/or in accordance with approved product label of the prescribed medications.

  • DrugLevodopa-Carbidopa Intestinal Gel

    Drug pages: Levodopa · Carbidopa

    Also known as: ABT-SLV187, Duodopa, LCIG

  • DeviceNasojejunal (NJ) tube

    optional prior to PEG-J placement

  • DevicePercutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 26 in the NMSS Total Score

    The NMSS consists of 30 questions in 9 domains (cardiovascular/falls, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, GI tract, urinary, sexual function, miscellaneous). Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Total score is the sum of 9 domains, and ranges from 0 to 360, with a lower value indicating a more desirable outcome. Repeated-measure analysis.

    Time frame: Baseline, Week 26

  2. Change From Baseline to Week 26 in the Modified PDSS-2 Total Score

    The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score

    The PDQ-8 is a disease-specific instrument designed to measure aspects of health relevant to PD. Eight questions including the mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort are assessed on a 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Summary index score is the sum of each question divided by 32 and multiplied by 100. Scores range from 0 to 100 with lower values desirable.

    Time frame: Baseline, Week 26

  2. Clinical Global Impression of Change (CGI-C) Final Score

    CGI-C score is a clinician's impression of a subject's change in status on a 7-point scale (1 = very much improved, 2 = much improved, 3 = minimally Improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse). Scores range from 1 to 7, with lower score desirable.

    Time frame: End of Treatment Period (up to Week 26)

  3. Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score

    UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part II scores range from 0 to 52 with lower value desirable.

    Time frame: Baseline, Week 26

  4. Change From Baseline to Week 26 in the NMSS Domain Scores

    The NMSS consists of 30 questions in 9 domains. Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Cardiovascular/falls scores range from 0 - 24 with lower value desirable. Sleep/fatigue scores range from 0 - 48 with lower value desirable. Mood/cognition scores range from 0 - 72 with lower value desirable. Perceptual problems/hallucinations scores range from 0 - 36 with lower value desirable. Attention/memory scores range from 0 - 36 with lower value desirable. Gastrointestinal tract scores range from 0 - 36 with lower value desirable. Urinary scores range from 0 - 36 with lower value desirable. Sexual function scores range from 0 - 24 with lower value desirable. Miscellaneous scores range from 0 - 48 with lower value desirable. Repeated-measure analysis.

    Time frame: Baseline, Week 26

  5. Change From Baseline to Week 26 in the Modified PDSS-2 Domain Scores

    The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.

    Time frame: Baseline, Week 26

  6. Change From Baseline at Week 26 in UPDRS Parts I, III, and IV Score

    UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part I is the sum of Questions 1 - 4; scores range from 0 to 16 with lower value desirable. Part III is the sum of Questions 18 - 31 (Questions 20 - 26 apply to multiple body parts, resulting in 27 answers total); scores range from 0 to 108 with lower value desirable. Part IV is the sum of Questions 32 - 42; scores range from 0 to 23 with lower value desirable.

    Time frame: Baseline, Week 26

  7. Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score

    PAS is a 12-item scale developed specifically to measure severity in anxiety in Parkinson's disease for the following items: Feeling anxious or nervous; Feeling tense or stressed; Being unable to relax; Excessive worrying about everyday matters; Fear of something bad, or even the worst, happening; Panic or intense fear; Shortness of breath; Heart palpitations or heart beating fast; Fear of losing control; Social situations; Public settings; Specific objects or situations. Severity for each item is rated as: 0, Never; 1 Rarely; 2, Sometimes; 3, Often; 4, Nearly always. Total score is the sum of the12 item scores, with a range of 0 to 48; a lower value is desirable.

    Time frame: Baseline, Week 26

  8. Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score

    The GDS-15 is a short, self-report reliable and valid screening instrument for depression in the elderly of 15 yes/no questions: 1) Satisfied with life 2) Dropped many activities and interests 3) Life is empty 4) Often get bored 5) In good spirits most of the time 6) Afraid that something bad is going to happen 7) Feel happy most of the time 8) Often feel helpless 9) Prefer to stay at home, rather than going out and doing things 10) Feel that have more problems with memory than most 11) Think it is wonderful to be alive now 12) Feel worthless 13) Feel full of energy 14) Situation is hopeless 15) Most subjects are better off. Answers of 'yes' to questions 2, 3, 4, 6, 8, 9, 10, 12, 14, 15 are scored 1 point. Answers of 'no' to questions 1, 5, 7, 11, 13 are scored 1 point. The 15 items are summed and scores range from 0 - 15 with lower value desirable.

    Time frame: Baseline, Week 26

  9. Change From Baseline at Week 26 in King's PD Pain Scale (KPPS) Score

    The KPPS score is a clinical PD-specific pain scale of 14 items addressing the following 7 domains: musculoskeletal pain, chronic pain, fluctuation-related pain, nocturnal pain, orofacial pain, neuropathic pain, radicular pain. Each domain item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 - 12 (with lower value desirable), the sum of the 14 items gives the total score with a range from 0 to 168 with lower value desirable.

    Time frame: Baseline, Week 26

  10. Patient Global Impression of Change (PGIC) Final Score

    The PGIC is a 7-point response scale. The participant was asked by the Investigator or qualified designee to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. PGIC score ranges from 1 to 7 with lower score desirable.

    Time frame: End of Treatment Period (up to Week 26)

07

Results

Posted Jun 3, 2021

Participant flow

This study was conducted at 32 sites in 9 countries.

Treatment Period
Participant flow — Treatment Period
MilestoneOptimized Medical TreatmentLCIG
Started4445
Completed4138
Not completed37
Withdrew: Adverse event22
Withdrew: Withdrawal by subject13
Withdrew: Lack of efficacy02
Extension/Transition Period
Participant flow — Extension/Transition Period
MilestoneOptimized Medical TreatmentLCIG
Started1014
Transitioned to commercial lcig57
Completed510
Not completed54
Withdrew: Adverse event11
Withdrew: Withdrawal by subject01
Withdrew: Other, not specified42

Outcome measures

PrimaryChange From Baseline to Week 26 in the NMSS Total Score

The NMSS consists of 30 questions in 9 domains (cardiovascular/falls, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, GI tract, urinary, sexual function, miscellaneous). Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Total score is the sum of 9 domains, and ranges from 0 to 360, with a lower value indicating a more desirable outcome. Repeated-measure analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 26 in the NMSS Total Score
score on a scaleOptimized Medical TreatmentLCIG
Change From Baseline to Week 26 in the NMSS Total Score-23.83 ± 8.30-32.04 ± 8.53
Statistical analysis
  • Optimized Medical Treatment vs LCIG · mixed model repeated measures · p = 0.410 (P value is from the mixed model repeated measures (MMRM) with the model: change from Baseline=treatment, country, visit, Baseline, treatment-by-visit, and Baseline-by-visit. Unstructured variance-covariance structure was used in the MMRM analysis.) · Least squares (ls) mean of difference: -8.21 · 95% CI -27.98 to 11.55Difference of LCIG - OMT
PrimaryChange From Baseline to Week 26 in the Modified PDSS-2 Total Score

The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 26 in the Modified PDSS-2 Total Score
score on a scaleOptimized Medical TreatmentLCIG
Change From Baseline to Week 26 in the Modified PDSS-2 Total Score-8.98 ± 2.00-7.41 ± 2.01
Statistical analysis
  • Optimized Medical Treatment vs LCIG · mixed model repeated measures · p = 0.509 (The P value is from the MMRM with the model: change from Baseline = treatment, country, visit, Baseline, treatment-by-visit, and Baseline-by-visit. The unstructured variance-covariance structure was used in the MMRM analysis.) · Ls mean of difference: 1.57 · 95% CI -3.16 to 6.30Difference of LCIG - OMT
SecondaryChange From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score

The PDQ-8 is a disease-specific instrument designed to measure aspects of health relevant to PD. Eight questions including the mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort are assessed on a 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Summary index score is the sum of each question divided by 32 and multiplied by 100. Scores range from 0 to 100 with lower values desirable.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score
score on a scaleOptimized Medical TreatmentLCIG
Change From Baseline to Week 26 in Parkinson's Disease Questionnaire (PDQ-8) Summary Index Score-1.75 ± 2.96-5.56 ± 2.97
Statistical analysis
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.291 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -3.81 · 95% CI -10.96 to 3.34Difference of LCIG - OMT
SecondaryClinical Global Impression of Change (CGI-C) Final Score

CGI-C score is a clinician's impression of a subject's change in status on a 7-point scale (1 = very much improved, 2 = much improved, 3 = minimally Improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse). Scores range from 1 to 7, with lower score desirable.

Time frame:
End of Treatment Period (up to Week 26)
Reported as:
Least squares mean · score on a scale
Clinical Global Impression of Change (CGI-C) Final Score
score on a scaleOptimized Medical TreatmentLCIG
Clinical Global Impression of Change (CGI-C) Final Score4.9 ± 0.252.5 ± 0.24
Statistical analysis
  • Optimized Medical Treatment vs LCIG · ANCOVA · p = < 0.001 (Analysis of covariance (ANCOVA) model: FINAL = treatment, country.) · Ls mean of difference: -2.3 · 95% CI -2.84 to -1.82Difference of LCIG - OMT
SecondaryChange From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score

UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part II scores range from 0 to 52 with lower value desirable.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score
score on a scaleOptimized Medical TreatmentLCIG
Change From Baseline at Week 26 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score0.53 ± 0.89-2.26 ± 0.87
Statistical analysis
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.006 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -2.79 · 95% CI -4.77 to -0.81Difference of LCIG - OMT
SecondaryChange From Baseline to Week 26 in the NMSS Domain Scores

The NMSS consists of 30 questions in 9 domains. Score of each question is calculated by multiplying severity\*frequency. Severity and frequency are rated using a scale ranging from 0 (none) to 3 (severe) for severity and from 1 (rarely) to 4 (very frequent) for frequency. Cardiovascular/falls scores range from 0 - 24 with lower value desirable. Sleep/fatigue scores range from 0 - 48 with lower value desirable. Mood/cognition scores range from 0 - 72 with lower value desirable. Perceptual problems/hallucinations scores range from 0 - 36 with lower value desirable. Attention/memory scores range from 0 - 36 with lower value desirable. Gastrointestinal tract scores range from 0 - 36 with lower value desirable. Urinary scores range from 0 - 36 with lower value desirable. Sexual function scores range from 0 - 24 with lower value desirable. Miscellaneous scores range from 0 - 48 with lower value desirable. Repeated-measure analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 26 in the NMSS Domain Scores
score on a scaleOptimized Medical TreatmentLCIG
Cardiovascular including falls-1.84 ± 0.82-1.76 ± 0.86
Sleep/fatigue-7.11 ± 2.02-6.06 ± 2.06
Mood/cognition-5.99 ± 3.06-7.84 ± 3.11
Perceptual problems/hallucinations-1.53 ± 0.70-1.14 ± 0.72
Attention/memory-1.20 ± 1.60-2.15 ± 1.66
Gastrointestinal tract-0.85 ± 1.09-3.43 ± 1.14
Urinary-3.65 ± 1.90-4.83 ± 1.96
Sexual function0.88 ± 0.860.10 ± 0.90
Miscellaneous-3.87 ± 1.53-5.16 ± 1.60
Statistical analysis
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.933 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: 0.08 · 95% CI -1.89 to 2.06Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.655 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: 1.05 · 95% CI -3.63 to 5.74Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.616 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -1.85 · 95% CI -9.18 to 5.48Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.645 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: 0.39 · 95% CI -1.30 to 2.08Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.645 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -0.94 · 95% CI -5.03 to 3.14Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.058 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -2.58 · 95% CI -5.25 to 0.09Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.588 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -1.18 · 95% CI -5.52 to 3.15Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.464 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -0.78 · 95% CI -2.88 to 1.33Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · Repeated measures model · p = 0.468 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean difference: -1.29 · 95% CI -4.80 to 2.23Difference of LCIG - OMT
SecondaryChange From Baseline to Week 26 in the Modified PDSS-2 Domain Scores

The PDSS-2 addresses PD-specific sleep disturbances such as restless leg syndrome (RLS), morning akinesia, pain, and sleep apnea. The frequency is assessed for the 15 sleep problems based on a 5-point Likert-type scale (ranging from 0 \[never\] to 4 \[very often\]). Scores are calculated for each of the 3 domains (motor symptoms at night, PD symptoms at night, and disturbed sleep) as well as a total score. The PDSS-2 domain scores range from 0 to 20 and the total score is a sum of the 3 domains and ranges from 0 to 60. Repeated measure analysis.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 26 in the Modified PDSS-2 Domain Scores
score on a scaleOptimized Medical TreatmentLCIG
Motor symptoms at night-2.21 ± 1.04-2.79 ± 1.05
PD symptoms at night-1.77 ± 0.66-1.53 ± 0.69
Disturbed sleep-4.88 ± 0.74-2.89 ± 0.75
Statistical analysis
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.643 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -0.58 · 95% CI -3.09 to 1.92Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.769 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: 0.24 · 95% CI -1.39 to 1.87Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.020 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: 1.99 · 95% CI 0.32 to 3.66Difference of LCIG - OMT
SecondaryChange From Baseline at Week 26 in UPDRS Parts I, III, and IV Score

UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease of 42 total questions. Part I (Questions 1 - 4), Part II (Questions 5 - 17), Part III (Questions 18 - 31), and Part IV (Questions 32 - 42). Questions 35 - 38 and 40 - 42 are 2-point (0 and 1), all other questions are 5-point (0 - 4). Part I is the sum of Questions 1 - 4; scores range from 0 to 16 with lower value desirable. Part III is the sum of Questions 18 - 31 (Questions 20 - 26 apply to multiple body parts, resulting in 27 answers total); scores range from 0 to 108 with lower value desirable. Part IV is the sum of Questions 32 - 42; scores range from 0 to 23 with lower value desirable.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 26 in UPDRS Parts I, III, and IV Score
score on a scaleOptimized Medical TreatmentLCIG
Part I0.20 ± 0.390.39 ± 0.39
Part III1.32 ± 1.84-0.89 ± 1.80
Part IV-0.61 ± 0.53-2.31 ± 0.52
Statistical analysis
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.672 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: 0.19 · 95% CI -0.72 to 1.10Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.302 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -2.22 · 95% CI -6.47 to 2.04Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.007 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -1.70 · 95% CI -2.91 to -0.48Difference of LCIG - OMT
SecondaryChange From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score

PAS is a 12-item scale developed specifically to measure severity in anxiety in Parkinson's disease for the following items: Feeling anxious or nervous; Feeling tense or stressed; Being unable to relax; Excessive worrying about everyday matters; Fear of something bad, or even the worst, happening; Panic or intense fear; Shortness of breath; Heart palpitations or heart beating fast; Fear of losing control; Social situations; Public settings; Specific objects or situations. Severity for each item is rated as: 0, Never; 1 Rarely; 2, Sometimes; 3, Often; 4, Nearly always. Total score is the sum of the12 item scores, with a range of 0 to 48; a lower value is desirable.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score
score on a scaleOptimized Medical TreatmentLCIG
Change From Baseline at Week 26 in Parkinson's Anxiety Scale (PAS) Total Score-0.75 ± 1.28-2.29 ± 1.27
Statistical analysis
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.307 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -1.54 · 95% CI -4.52 to 1.44Difference of LCIG - OMT
SecondaryChange From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score

The GDS-15 is a short, self-report reliable and valid screening instrument for depression in the elderly of 15 yes/no questions: 1) Satisfied with life 2) Dropped many activities and interests 3) Life is empty 4) Often get bored 5) In good spirits most of the time 6) Afraid that something bad is going to happen 7) Feel happy most of the time 8) Often feel helpless 9) Prefer to stay at home, rather than going out and doing things 10) Feel that have more problems with memory than most 11) Think it is wonderful to be alive now 12) Feel worthless 13) Feel full of energy 14) Situation is hopeless 15) Most subjects are better off. Answers of 'yes' to questions 2, 3, 4, 6, 8, 9, 10, 12, 14, 15 are scored 1 point. Answers of 'no' to questions 1, 5, 7, 11, 13 are scored 1 point. The 15 items are summed and scores range from 0 - 15 with lower value desirable.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score
score on a scaleOptimized Medical TreatmentLCIG
Change From Baseline at Week 26 in Geriatric Depression Scale (GDS-15) Score0.25 ± 0.400.17 ± 0.39
Statistical analysis
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.868 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -0.08 · 95% CI -0.99 to 0.84Difference of LCIG - OMT
SecondaryChange From Baseline at Week 26 in King's PD Pain Scale (KPPS) Score

The KPPS score is a clinical PD-specific pain scale of 14 items addressing the following 7 domains: musculoskeletal pain, chronic pain, fluctuation-related pain, nocturnal pain, orofacial pain, neuropathic pain, radicular pain. Each domain item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 - 12 (with lower value desirable), the sum of the 14 items gives the total score with a range from 0 to 168 with lower value desirable.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · score on a scale
Change From Baseline at Week 26 in King's PD Pain Scale (KPPS) Score
score on a scaleOptimized Medical TreatmentLCIG
Total score-11.32 ± 2.83-12.46 ± 2.77
Musculoskeletal Pain Score-1.72 ± 0.63-1.79 ± 0.62
Chronic pain score-0.84 ± 0.54-0.77 ± 0.55
Fluctuation related pain score-3.77 ± 1.30-3.14 ± 1.28
Nocturnal pain score-2.41 ± 1.04-2.78 ± 1.01
Orofacial pain score-0.74 ± 0.41-0.87 ± 0.41
Discoloration and edema score-0.47 ± 0.65-2.27 ± 0.65
Radicular pain score-1.43 ± 0.39-1.47 ± 0.39
Statistical analysis
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.728 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -1.14 · 95% CI -7.68 to 5.39Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.916 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -0.08 · 95% CI -1.50 to 1.35Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.919 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: 0.07 · 95% CI -1.28 to 1.42Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.680 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: 0.63 · 95% CI -2.42 to 3.68Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.767 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -0.37 · 95% CI -2.83 to 2.09Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.804 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -0.13 · 95% CI -1.15 to 0.90Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.025 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -1.81 · 95% CI -3.38 to -0.23Difference of LCIG - OMT
  • Optimized Medical Treatment vs LCIG · repeated measures model · p = 0.930 (The repeated measures model: change = treatment, country, visit, baseline, treatment \* visit, baseline \* visit. The unstructured variance-covariance structure is used.) · Ls mean of difference: -0.04 · 95% CI -0.99 to 0.90Difference of LCIG - OMT
SecondaryPatient Global Impression of Change (PGIC) Final Score

The PGIC is a 7-point response scale. The participant was asked by the Investigator or qualified designee to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. PGIC score ranges from 1 to 7 with lower score desirable.

Time frame:
End of Treatment Period (up to Week 26)
Reported as:
Least squares mean · score on a scale
Patient Global Impression of Change (PGIC) Final Score
score on a scaleOptimized Medical TreatmentLCIG
Patient Global Impression of Change (PGIC) Final Score4.9 ± 0.252.5 ± 0.24
Statistical analysis
  • Optimized Medical Treatment vs LCIG · ANCOVA · p = < 0.001 (ANCOVA model: FINAL = treatment, country.) · Ls mean of difference: -2.4 · 95% CI -2.89 to -1.87Difference of LCIG - OMT

Adverse events

Collected over All adverse events are reported from the time of randomization until 30 days following last OMT dose, last study visit, discontinuation of study drug administration, removal of the PEG-J tube or Last LCIG Commercial Transition Visit have elapsed. Median duration of follow-up was 191 days for OMT and 565 days for LCIG in the Treatment Period, and was 1366 days for OMT -> LCIG and 1003.5 days for LCIG -> LCIG in the Extension/Transition period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Optimized Medical Treatment (OMT)0/44 (0%)4/44 (9.1%)13/44 (29.5%)
LCIG0/45 (0%)9/43 (20.9%)33/43 (76.7%)
Extension/Transition OMT->LCIG1/10 (10%)2/10 (20%)6/10 (60%)
Extension/Transition LCIG->LCIG0/14 (0%)1/14 (7.1%)4/14 (28.6%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventOptimized Medical Treatment (OMT)LCIGExtension/Transition OMT->LCIGExtension/Transition LCIG->LCIG
AORTIC VALVE STENOSISCardiac disorders0/440/431/100/14
ILEUS PARALYTICGastrointestinal disorders0/440/431/100/14
ASTHENIAGeneral disorders0/440/431/100/14
DEATHGeneral disorders0/440/431/100/14
PERITONITISInfections and infestations0/440/431/100/14
PNEUMONIAInfections and infestations0/440/431/100/14
SYNCOPENervous system disorders0/440/431/100/14
DYSPNOEARespiratory, thoracic and mediastinal disorders0/440/431/100/14
PNEUMONIA ASPIRATIONRespiratory, thoracic and mediastinal disorders0/440/431/100/14
ROTATOR CUFF SYNDROMEMusculoskeletal and connective tissue disorders0/440/430/101/14
Most frequent other events
Showing 10 of 46
Most frequent other events
EventOptimized Medical Treatment (OMT)LCIGExtension/Transition OMT->LCIGExtension/Transition LCIG->LCIG
STOMA SITE PAINInjury, poisoning and procedural complications0/446/433/101/14
DYSKINESIANervous system disorders1/444/432/100/14
FALLInjury, poisoning and procedural complications7/444/430/100/14
ABDOMINAL PAINGastrointestinal disorders0/445/431/101/14
STOMA SITE INFECTIONInfections and infestations0/445/431/100/14
ABDOMINAL DISCOMFORTGastrointestinal disorders0/440/431/100/14
ABDOMINAL DISTENSIONGastrointestinal disorders0/442/431/100/14
DUODENAL ULCERGastrointestinal disorders0/441/431/100/14
DYSPEPSIAGastrointestinal disorders0/440/431/100/14
DYSPHAGIAGastrointestinal disorders0/440/431/100/14

Baseline characteristics

Safety dataset: all participants randomized to OMT, and all participants randomized to LCIG who had study device (NJ and/or PEG-J) placement.

Age, Continuous
Age, Continuous(years)Optimized Medical TreatmentLCIGTotal
Mean68.6 ± 6.2166.9 ± 7.3467.8 ± 6.81
Sex: Female, Male
Sex: Female, Male(Participants)Optimized Medical TreatmentLCIGTotal
Female201434
Male242953
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Optimized Medical TreatmentLCIGTotal
Hispanic or Latino9716
Not Hispanic or Latino353671
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Optimized Medical TreatmentLCIGTotal
American Indian or Alaska Native000
Asian9817
Native Hawaiian or Other Pacific Islander000
Black or African American011
White353469
More than one race000
Unknown or Not Reported000
Non-Motor Symptoms Scale (NMSS) Total Score
Non-Motor Symptoms Scale (NMSS) Total Score(score on a scale)Optimized Medical TreatmentLCIGTotal
Mean112.4 ± 51.3799.7 ± 46.49106.2 ± 49.14
Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score
Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score(score on a scale)Optimized Medical TreatmentLCIGTotal
Mean30.3 ± 8.5529.9 ± 7.3630.1 ± 7.94
08

Study locations

38 sites
  • Parkinson's and Movement /ID# 161596
    Fountain Valley, California 92708, United States
  • Boca Raton Regional Hospital /ID# 200056
    Boca Raton, Florida 33486, United States
  • University of Florida Neurolog /ID# 168699
    Jacksonville, Florida 32209, United States
  • Parkinson's Disease Treatment Center of Southwest Florida /ID# 168085
    Port Charlotte, Florida 33980, United States
  • Rush University Medical Center /ID# 168088
    Chicago, Illinois 60612, United States
  • St. Luke's Health System /ID# 168706
    Kansas City, Missouri 64111, United States
  • Central Texas Neurology Consul /ID# 168087
    Round Rock, Texas 78681, United States
  • Inland Northwest Research /ID# 200113
    Spokane, Washington 99202-1342, United States
  • Westmead Hospital /ID# 136575
    Westmead, New South Wales 2145, Australia
  • Royal Adelaide Hospital /ID# 136577
    Adelaide, South Australia 5000, Australia
  • Royal Melbourne Hospital /ID# 136780
    Parkville, Victoria 3050, Australia
  • Goulburn Valley Hospital /ID# 164202
    Shepparton, Victoria 3630, Australia
  • University of Alberta /ID# 136586
    Edmonton, Alberta T6G 2X8, Canada
  • The Ottawa Hospital /ID# 139341
    Ottawa, Ontario K1H 8L6, Canada
  • Toronto Western Hospital /ID# 136585
    Toronto, Ontario M5T 2S8, Canada
  • Central Hospital Bremerhaven /ID# 136573
    Bremerhaven, 27574, Germany
  • 251 Airforce General Hospital /ID# 160594
    Athens, Attiki 11525, Greece
  • Mediterraneo Hospital /ID# 208042
    Glyfada, 16675, Greece
  • A.O. Univ. Ospedali Riuniti /ID# 135964
    Ancona, Marche 60126, Italy
  • Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 136789
    Bologna, 40139, Italy
  • A.O.U. Ospedali Riuniti di Fog /ID# 136792
    Foggia, 71100, Italy
  • A.O.U. Policlinico G. Martino /ID# 136790
    Messina, 98125, Italy
  • Ospedale S.Maria della Miseri /ID# 160609
    Perugia, 06132, Italy
  • Azienda Sanitaria Locale di /ID# 160608
    Ponderano,biella, 13875, Italy
  • Azienda Policlinico Umberto I /ID# 201223
    Roma, 00161, Italy
  • Severance Hospital /ID# 163019
    Seoul, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Seoul National University Hospital /ID# 162990
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center /ID# 163018
    Seoul, 05505, Korea, Republic of
  • Hospital Universitario de Bellvitge /ID# 136579
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • CHU Insular-Materno Infantil /ID# 136783
    Las Palmas de Gran Canaria, Las Palmas 35016, Spain
  • Hospital Clinic de Barcelona /ID# 137689
    Barcelona, 08036, Spain
  • Hospital Santa Creu i Sant Pau /ID# 136581
    Barcelona, 08041, Spain
  • Hospital Puerta del Mar /ID# 157977
    Cadiz, 11009, Spain
  • Hospital Universitario Virgen de las Nieves /ID# 136583
    Granada, 18014, Spain
  • Hospital Universitario Ramon y Cajal /ID# 136784
    Madrid, 28034, Spain
  • Hospital Universitario Virgen del Rocio /ID# 145624
    Sevilla, 41013, Spain
  • Hospital Universitario y Politecnico La Fe /ID# 136722
    Valencia, 46026, Spain
  • Karolinska Univ Sjukhuset /ID# 135961
    Solna, 17176, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in May 2020, 54 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 54 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2015
First posted
Sep 15, 2015
StartActual
Oct 26, 2015
Primary completionActual
May 14, 2020
CompletionActual
Nov 18, 2022
Results first posted
Jun 3, 2021
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02549092
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 15, 2015
Start date
Oct 26, 2015
Primary completion
May 14, 2020
Completion
Nov 18, 2022
Results posted
Jun 3, 2021
Last update
Nov 28, 2023

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa

Start the discussion